CEO defends raising price of drug from $13.50 a pill to $750: 'We have to turn a profit'
A former hedge fund manager is justifying his startup company's decision to increase the price of a life-saving drug from $13.50 per pill to $750 by saying it's necessary in order to create better medicine in the future.
Martin Shkreli's Turing Pharmaceuticals acquired the drug Daraprim in August, The Guardian reports. Daraprim is used to treat toxoplasmosis, a parasitic infection that can be fatal when it affects babies born to infected mothers and people with compromised immune systems due to AIDS and certain cancers. Shkreli told Bloomberg News on Monday the company needs to "turn a profit on the drug," since research is costly and they want to come up with a newer version. Daraprim is the trade name for the generic drug pyrimethamine, which was developed in the 1940s and is on the World Health Organization's List of Essential Medicines.
The HIV Medicine Association and the Infectious Diseases Society of America sent a letter to Turing Pharmaceuticals earlier in September, and said the 50-fold increase in price was "unjustifiable for the medically-vulnerable patient population" and "unsustainable for the health care system." Shkreli said Monday Daraprim is actually underpriced, and declared: "If you cannot afford the drug we will give it away for free."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
Why Man United finally lost patience with ten Hag
Talking Point After another loss United sacked ten Hag in hopes of success in the Champion's League
By The Week UK Published
-
Who are the markets backing in the US election?
Talking Point Speculators are piling in on the Trump trade. A Harris victory would come as a surprise
By The Week UK Published
-
Crossword: November 3, 2024
The Week's daily crossword
By The Week Staff Published
-
Nobody seems surprised Wagner's Prigozhin died under suspicious circumstances
Speed Read
By Peter Weber Published
-
Western mountain climbers allegedly left Pakistani porter to die on K2
Speed Read
By Justin Klawans Published
-
'Circular saw blades' divide controversial Rio Grande buoys installed by Texas governor
Speed Read
By Peter Weber Published
-
Los Angeles city workers stage 1-day walkout over labor conditions
Speed Read
By Justin Klawans Published
-
Mega Millions jackpot climbs to an estimated $1.55 billion
Speed Read
By Catherine Garcia Published
-
Bangladesh dealing with worst dengue fever outbreak on record
Speed Read
By Catherine Garcia Published
-
Glacial outburst flooding in Juneau destroys homes
Speed Read
By Catherine Garcia Published
-
Scotland seeking 'monster hunters' to search for fabled Loch Ness creature
Speed Read
By Justin Klawans Published